FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

A novel approach to multiple myeloma treatment developed by Bristol-Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) took an important step toward commercialization on Tuesday when the Food and Drug Administration announced that it had accepted their application for approval of ide-cel, also known as bb2121.

A chimeric antigen receptor T-cell (CAR-T) therapy, ide-cel elicited a 73% overall response rate in multiple myeloma patients whose disease had returned following a median of three previous treatments.

A person speaks through a megaphone.


The biotech companies specifically engineered ide-cel to trigger cancer cell death by recognizing and binding to B-cell maturation antigen, or BCMA, a protein expressed predominately by multiple myeloma cells.

In addition to its high overall response rate, 33% of heavily pretreated multiple myeloma patients had a complete response to ide-cel in clinical trials. The median duration of response was 10.7 months and median progression-free survival was 8.8 months. In terms of safety, 84% of patients experienced cytokine release syndrome, or CRS, a potentially life-threatening condition that's common in currently approved CAR-T therapies. Of these cases, 78% were mild or moderate.

An FDA decision on ide-cel is expected on March 27. If the treatment is approved, it will enter a competitive indication. The most widely used multiple myeloma drugs generate billions in revenue annually, including Bristol-Myers' Revlimid, which posted sales of $2.9 billion in the second quarter.

10 stocks we like better than Bristol Myers Squibb
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


Todd Campbell owns shares of Bluebird Bio and Bristol-Myers Squibb. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Bluebird Bio and Bristol Myers Squibb. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.